[HTML][HTML] Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer
V Subbiah, RJ Kreitman, ZA Wainberg… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK
inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, …
inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, …
Immunotoxin therapy of cancer
…, R Hassan, DJ FitzGerald, RJ Kreitman - Nature Reviews Cancer, 2006 - nature.com
Rationally designed anticancer agents that target cell-surface antigens or receptors represent
a promising approach for treating cancer patients. However, antibodies that bind these …
a promising approach for treating cancer patients. However, antibodies that bind these …
[HTML][HTML] Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
V Subbiah, RJ Kreitman, ZA Wainberg, A Gazzah… - Nature medicine, 2023 - nature.com
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
[HTML][HTML] Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
RJ Kreitman, WH Wilson, K Bergeron… - … England Journal of …, 2001 - Mass Medical Soc
Background Hairy-cell leukemia that is resistant to treatment with purine analogues, including
cladribine, has a poor prognosis. We tested the safety and efficacy of an immunotoxin …
cladribine, has a poor prognosis. We tested the safety and efficacy of an immunotoxin …
Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies
RJ Kreitman, WH Wilson, JD White… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To evaluate the toxicity, pharmacokinetics, immunogenicity, and antitumor activity
of anti-Tac(Fv)-PE38 (LMB-2), an anti-CD25 recombinant immunotoxin that contains an …
of anti-Tac(Fv)-PE38 (LMB-2), an anti-CD25 recombinant immunotoxin that contains an …
Immunotoxin treatment of cancer
…, R Hassan, DJ FitzGerald, RJ Kreitman - Annu. Rev. Med., 2007 - annualreviews.org
Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment
linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell …
linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell …
[HTML][HTML] Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
RJ Kreitman, MS Tallman, T Robak… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
… Employment or Leadership Position: Robert Lechleider, former employee of MedImmune
(C) Consultant or Advisory Role: None Stock Ownership: None Honoraria: None Research …
(C) Consultant or Advisory Role: None Stock Ownership: None Honoraria: None Research …
Immunotoxins for targeted cancer therapy
RJ Kreitman - The AAPS journal, 2006 - Springer
Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that
binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting …
binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting …
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and …
R Hassan, S Bullock, A Premkumar, RJ Kreitman… - Clinical Cancer …, 2007 - AACR
Purpose: To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics
of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with …
of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with …
[HTML][HTML] Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries
…, LS Irby, MG Ison, NT Joseph, HB Kim, RJ Kreitman… - Nature …, 2022 - nature.com
The chr12q24.13 locus encoding OAS1–OAS3 antiviral proteins has been associated with
coronavirus disease 2019 (COVID-19) susceptibility. Here, we report genetic, functional and …
coronavirus disease 2019 (COVID-19) susceptibility. Here, we report genetic, functional and …
